Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis

Hutchinson, Carol; Geissler, Catherine A.; Powell, Jonathan J.; Bomford, Adrian
September 2007
Gut;Sep2007, Vol. 56 Issue 9, p1291
Academic Journal
Background and Aims: During the long-term treatment of patients with hereditary haemochromatosis (HH) the authors observed that proton pump inhibitors (PPI) reduced the requirement for maintenance phlebotomy. Gastric acid plays a crucial role in non-haem iron absorption and the authors performed a case review and intervention study to investigate if PPI-induced suppression of gastric acid would reduce dietary iron absorption in C282Y homozygous patients. Methods: Phlebotomy requirements to keep serum ferritin ∼50 μg/l before (mean 6.1 (SE 0.6) years) and during (3.8 (0.9) years) administration of a PPI were evaluated in seven patients and a post-prandial study was performed to determine whether PPIs reduce absorption of non-haem iron (14.5 mg) from a test meal in a further 14 phlebotomised patients with normal iron stores. Results: There was a significant reduction (p<0.001) in the volume of blood removed annually before (2.5 (0.25) I) and while taking (0.5 (0.25) I) a PPI. Administration of a PPI for 7d suppressed absorption of non-haem iron from the meal as shown by a significant reduction (all p<0.01) in: area under the serum curve (2145 (374) versus 1059 (219)), % recovery of administered iron at peak serum iron (20.5 (3.2) versus 11.0 (2.0)%) and peak serum iron (13.6 (2.4) vs 6.1 (1.2) μmol/l) (all values are before vs during PPI). Conclusions: Administration of a PPI to patients with HH can inhibit the absorption of non-haem iron from a test meal and the habitual diet.


Related Articles

  • PPIs and Clopidogrel: Do We Have to Worry? Kuritzky, Louis // OB/GYN Clinical Alert;Dec2009, Vol. 26 Issue 8, p23 

    The article reports on the pharmacological relation between proton pump inhibitor (PPI) and clopidogrel in the U.S. It mentions that the antiplatelet effect of clopidogrel depends on its conversion and activation through the 2C19 pathway of the P450 system where the blockade of this pathway...

  • PPIs, H. pylori, and Atrophic Gastritis: Putting the Issue to Rest? DiBaise, John K.; Thompson, Jon S. // American Journal of Gastroenterology;Dec1999, Vol. 94 Issue 12, p3403 

    Discusses research being done on the effect of acid suppression therapy on the development of atrophic gastritis in individuals infected with Helicobacter pylori. Reference to a study by L. Lundell, P. Miettinen, H. E. Myrvold et al., published in the 1999 issue of the "American Journal of...

  • Gastro-oesophageal reflux disease.  // BMJ: British Medical Journal (International Edition);1/14/2006, Vol. 332 Issue 7533, p88 

    The article discusses the causes, diagnosis and treatment of gastro-oesophageal reflux disease (GORD). The author reviews how GORD is present when the passage of gastric contents into the oesophagus causes symptoms or damages the mucosa. According to the author, genetic influences and lifestyle...

  • PPI treatment beneficial to patients with ulcer bleeding, according to meta-analysis.  // Formulary;Jun2007, Vol. 42 Issue 6, p391 

    The article focuses on the study that examines the benefits of proton-pump inhibitors (PPIs) for patients with ulcer bleeding. According to the study, the use of PPIs for ulcer bleeding effectively reduces the risk of bleeding and the need for surgical intervention and repeated endoscopic...

  • PPI USE AND HIP FRACTURE RISK.  // Pulse;4/19/2007, Vol. 67 Issue 15, p42 

    The article focuses on the therapeutic effect of proton pump inhibitors (PPIs) in increasing the risk of hip fracture. Study shows that significant hypochlorhydria may cause calcium malabsorption that result in higher risk of bone fractures. The cumulative duration of PPI therapy for up to four...

  • Interaction between liquid protein solution and omeprazole suspension.  // American Journal of Health-System Pharmacy;11/1/2009, Vol. 66 Issue 21, p1901 

    The article discusses the use of proton-pump inhibitors (PPI) in preventing stress-related mucosal bleeding. It cites the reaction of omeprazole capsules combined with sodium bicarbonate in patients. It also examines the reaction of omeprazole suspension combined with ingredients of protein...

  • Inhibidores de bomba de protones y clopidogrel: Evidencia de interacción farmacológica de gran impacto clínico. Martínez, Ingrid; Coy, Vivian; Otero, William // Revista Colombiana de Gastroenterología;Mar2010, Vol. 25 Issue 1, p68 

    Clopidogrel, a thienopyridine, is an antiplatelet drug which currently represents the cornerstone for the treatment of acute coronary events. It is a pro-drug that must be converted at hepatic level into its active form by the CYP2C19 isoenzyme. Recently the interaction between proton pump...

  • Use of proton pump inhibitors in hematopoietic stem cell transplantation does not increase the frequency of febrile neutropenia. OZKAN, M. C.; DONMEZ, A.; ARSLAN, A.; AYDEMIR, S.; TOMBULOGLU, M. // European Review for Medical & Pharmacological Sciences;Nov2015, Vol. 19 Issue 21, p4105 

    OBJECTIVE: Despite the fact that proton pump inhibitor (PPI) use is a risk factor for infections in heterogeneous groups of patients, there are only a limited data related to PPI use and febrile neutropenic episodes (FNEs) in hematopoietic stem cell transplantation (HSCT) patients. PATIENTS AND...

  • What are the precautions with proton pump inhibitor use for reflux disease? Mospan, Courtney M. // JAAPA: Journal of the American Academy of Physician Assistants (;Dec2015, Vol. 28 Issue 12, p23 

    No abstract available.


Read the Article


Sign out of this library

Other Topics